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Introduction: The mortality rate in low rectal cancer is related to pelvic and distant recur-
rence. For stage I tumors, local excision has being used increasingly, but recent studies show
the  need for caution with the use of this technique, as they do not consider the possibility
of  a positive node in stage I rectal tumors. Therefore, preoperative radiotherapy should be
considered for early tumors, as an attempt to prevent recurrence.
Objective: Show the effectiveness of neoadjuvant radiotherapy in stage I cancer of the lower
rectum of a cohort population.
Material and method: A cohort study in a prospective database was made with a total of 538
patients, of which were considered 75 patients with stage I lower rectal cancer. Preoperative
radiotherapy was performed and patients were followed up for a minimum period of ﬁve
years.
Results: Stage I/TI group had 27 patients. All of them presented complete response to the
treatment and did not need to be operated. During the follow up time of ﬁve years, this
group showed no recurrence rate. The stage I/TII group had 48 patients. During the follow
up,  8 patients had to be operated due to suspicious lesion or scar. They were submitted to
full  total local excision. After evaluating the pathological specimen, none of them proved to
be  adenocarcinoma.
Conclusion: Preoperative radiation, not only reduced the local recurrence and mortality rate
in  lower rectal cancer, but also reduced the need for surgery in patients with stage I cancer.©  2015 Sociedade Brasileira de Coloproctologia. Published by Elsevier Editora Ltda. All
rights reserved.∗ Corresponding author.
E-mails: antonio xxxv@yahoo.com.br, reisneto@lexxa.com.br (A.J.T. Alves Júnior).
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Introduc¸ão: O percentual de mortalidade em pacientes com câncer de reto baixo está rela-
cionado a recorrências pélvica e remota. No caso de tumores no estágio I, a excisão local vem
sendo utilizada cada vez mais; contudo, estudos recentemente publicados demonstraram a
necessidade de se ter cautela com o uso dessa técnica, por não se levar em considerac¸ão a
possibilidade de um nodo positivo em tumores de reto no estágio I. Portanto, a radioterapia
pré-operatória é uma opc¸ão viável para os tumores em fase inicial, como uma tentativa de
evitar recorrência.
Objetivo: Demonstrar a eﬁcácia da radioterapia neoadjuvante em casos de câncer de reto
baixo no estágio I em uma coorte da populac¸ão.
Materiais e métodos: Foi realizado um estudo de coorte em um banco de dados prospec-
tivo, com envolvimento, no total, de 538 pacientes, dos quais 75 foram considerados como
tendo câncer de reto baixo no estágio I. No pré-operatório, os pacientes foram tratados com
radioterapia e seguidos durante um período mínimo de 5 anos.
Resultados: O Grupo no estágio I/TI consistia em 27 pacientes. Todos obtiveram resposta
completa ao tratamento e não houve necessidade de reoperac¸ão. Durante o período de 5
anos  de seguimento, não houve recorrências nesse grupo. O grupo no estágio I/TII consistia
em  48 pacientes. Durante o seguimento, 8 pacientes tiveram que ser operados, devido à sus-
peita de lesão, ou cicatriz. Para esses casos, optou-se por excisão local total completa. Após
a  avaliac¸ão dos espécimes patológicos, nenhum deles teve diagnóstico de adenocarcinoma.
Conclusão: O uso da radiac¸ão pré-operatória não só diminuiu a recorrência local e o
percentual de mortalidade em casos de câncer de reto baixo, mas também diminuiu a
necessidade de cirurgia em pacientes com câncer no estágio I.
©  2015 Sociedade Brasileira de Coloproctologia. Publicado por Elsevier Editora Ltda.
Todos os direitos reservados.
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reoperative radiotherapy in cancer of the lower rectum has
een used since 1975.1 However, during the last decade sub-
tantial progress has been made in treatment modalities. The
urgical management currently includes a broad spectrum of
perative procedures ranging from radical operations to inno-
ative sphincter-preserving techniques; new and improved
adiation techniques emerged (conformal radiotherapy, intra-
perative radiotherapy) with or without combinations of
hemotherapies.2–5 The mortality rate is related to pelvic and
istant recurrence.6 Therefore, adequate surgical technique is
andatory in the treatment of the rectal cancer.6,7 Also crit-
cal is the role of prognostic factors such as the pathologic T
tumor) and N (nodal) classiﬁcation, circumferential resection
argin, and response to preoperative therapy.3 Nodes can be
ositive even in early tumors.8
For stage I rectal cancer, local excision has being used
ncreasingly, but recent studies show the need for caution
ith the use of this technique, as they do not consider the
ossibility of a positive node in stage I rectal tumors.3,7,8
Nowadays, appropriate staging plays an increasingly
mportant role, because many  treatment decisions must be
ased on preoperative staging.2,3
Current guidelines advocate for neoadjuvant treatment for
tage II and III tumors, once it has been proved that preop-
rative radiation reduces local recurrence risk and improve
ong-term survival.9–12However, knowing that pre-operative radiotherapy is able
to decrease, signiﬁcantly, the number of undifferentiated cells;
diminish the grade of tumor invasion in the rectal wall; reduce,
statistically, the incidence of local recurrence and alter long-
term survival rate leads to believe that neoadjuvant therapy
should be used in early tumors as well, preventing a recur-
rence rate many  times reported in stage I patients.1
Objectives
Show the effectiveness of neoadjuvant radiotherapy in stage I
cancer of the lower rectum of a cohort population.
Methods
A cohort study in a prospective database was made from 1978
to 2012, with a total of 538 patients with lower rectum can-
cer, of which were considered 75 patients with stage I cancer.
These individuals were submitted to preoperative radiothe-
rapy. They were 27 patients stage I/TI and 48 patients stage
I/T2. All of them had lower rectum adenocarcinoma and were
followed by a 5-year minimum.
There was no gender, race and age distinction.
Preoperative dosage of CEA, gamma GT, colonoscopy and
abdominal ultrasound were performed in all the patients to
stage the tumor. When available endorectal ultrasound was
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Fig. 2 – Follow up results after 5 years.6  j coloproctol (r
performed to evaluate size and inﬁltration of the tumor before
and after the irradiation.
Proctoscopy and digital examination were performed at
diagnosis and after the end of the irradiation treatment to
evaluate tumor extension and wall inﬁltration.
Preoperative radiotherapy was performed with
200 cGy/daily for 4 consecutive weeks up to a total of 4500 cGy,
by means of a linear megavoltage accelerator (25 MeV), in
anterior and posterior pelvic ﬁelds.
Post-radiation protocol included periodical examination
every 3 months for the ﬁrst two years, with digital exami-
nation (or careful perineal palpation) and evaluation of the
CEA and every 6 months for the next consecutive three years.
Abdominal ultrasound was performed yearly and colonoscopy
every other year. When clinical assessment suggested local or
general recurrence, a CT scan or MR  was accomplished.
Results
The 75 patients with lower rectum cancer were followed for a
minimum period of 5 years.
The stage I/TI group had 27 patients, all of them submitted
to the same protocol of neoadjuvant therapy. Everyone pre-
sented complete response to the treatment and did not need
to be operated. During the follow up time of ﬁve years, this
group showed no recurrence rate.
The stage I/TII group had 48 patients, all of them submitted
to the same protocol of neoadjuvant therapy. During the follow
up, 8 patients had to be operated due to suspicious lesion or
scar. They were submitted to full total local excision. After
evaluating the pathological specimen, none of them proved
to be adenocarcinoma. It was found dysplasia and adenoma
(Fig. 1).
One patient of this group had a distant metastasis, after 5
years that occurred in the lungs (Fig. 2).
The other 40 patients had complete response after neoad-
juvant radiotherapy.Discussion
Treatment of rectal cancer has dramatically evolved during
the last three decades shifting toward a tailored approach
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Fig. 1 – Operated patients.based on preoperative staging and response to neoadjuvant
therapy.13
Preoperative radiotherapy reduces the risk of local recur-
rence in patients with operable rectal cancer and recurrence,
especially locally, is responsible for the great majority of
deaths in the ﬁrst two years after surgery.14
Previous studies showed that there is a signiﬁcant dif-
ference in the ﬁve-year survival rates in patients receiving
preoperative radiotherapy, who had a corrected survival rate
of 80% versus 34.4% of nonirradiated patients. The local recur-
rence rate was 2.9% in patients that received neoadjuvant
therapy versus 23.5% in those who had not.1
Endorectal ultrasound (ERUS) displays accuracy of 71–91%
and 69–97% for T stage, and 62–83% for nodal staging.15 Results
conﬁrmed in 200 patients, that after the irradiation an involu-
tion of the tumor size and volume occurred.1
Comparing to other studies when preoperative radiothe-
rapy was not used the recurrence rate was much higher.15–19
According to Aguilar, patients undergoing local resection
presented recurrence rate of 18% (T1) and 37% (T2) with 54
months of follow-up.
Paty et al. showed rates of 17–74% for T1 rectal cancers and
26–72% for T2 cancers with a median time to relapse of 1.4
years (range 0.4–7.0).
Patients undergoing local excision with transanal endo-
scopic microsurgery presented recurrence of 13% (T1), 17% (T2)
with follow up of 24 months.18
Bebenek showed 4.4% recurrence rate for T1 and T2 in two
year follow up after abdominoperineal resection.20
On the other hand, Lezoch showed a recurrence rate simi-
lar to the one presented in this study, with no recurrence in T1
and 2.85% in T2. The similar results are due to the use preoper-
ative radiotherapy before performing a transanal endoscopic
microsurgery.21,22
Those results shown that receiving neoadjuvant therapy
carries less risk of local recurrence than surgical techniques
that did not receive pre operative radiotherapy (local exci-
sion, transanal endoscopic microsurgery, abdominoperineal
resection, low anterior resection) (Table 1).A decrease of lymphatic invasion in patients that received
preoperative radiotherapy is observed, and also conﬁrmed
j coloproctol (rio j). 2
Table 1 – Risk of local recurrence.
Local recurrence T1 T2 Surgery
Aguilar (2000) 18% 37% LR
Paty (2002) 17–74% 26–76% LR
Stipa (2004) 13% 17% TEM
Bebenek (2009) 4.4% 4.4% APR
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2Lezoch (2002) – 2.85% RDT + TEM
Reis Neto (2012) – 2.6% RDT + SUR
hrough endorectal ultrasound, digital examination and endo-
copic an involution on the size and volume of the tumor.23,24
This study did not contemplate the possible complications
resented by radiotherapy or alluded to molecular analysis
ince this was not its goal.
onclusion
n this cohort, the use of neoadjuvant radiotherapy reduced
he risk of local recurrence, the mortality rate, and the needed
f surgery in stage 1 cancer of the lower rectum.
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